Overview

Public BiotechLSDHiring

Developing COMP360 synthetic psilocybin therapy for treatment-resistant depression. Currently in Phase 3 trials with Breakthrough Therapy designation from FDA. Headquartered in London with offices in New York.

Visit Website

London, UK

$850M
Market Cap
2016
Founded
150
Employees
34
Open Roles

Open Positions(34)

West Coast, United States
London, United Kingdom
London, United Kingdom
London, UK
Full-time
London, United Kingdom
New York, NY
Full-time
New York, NY
Contract
London, UK
Full-time
New York, United States
New York, United States
New York, United States

Clinical Pipeline(1)